Alan S Kliger, MD
he/him/his
DownloadHi-Res Photo
About
Biography
Dr. Kliger is Clinical Professor of Medicine, Yale School of Medicine. He served as Sr. VP Medical Affairs for Yale New Haven Health System, and was its Chief Quality Officer. He also served the Hospital of St. Raphael, New Haven as Chairman of the Department of Medicine, and later its Chief Medical Officer. Dr. Kliger currently serves as the Chair of the American Society of Nephrology's Excellence in Patient Care Advisory Committee. Dr. Kliger has co-authored more than 190 publications in peer-reviewed journals, with particular interest in dialysis, quality measurement, quality improvement and patient safety.
Appointments
Internal Medicine
Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- MD
- SUNY Upstate Med Center (1970)
- BS
- City College of New York (1966)
Board Certifications
Nephrology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1976
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1973
Research
Overview
Clinical research in areas of chronic kidney disease, hemo- and peritoneal dialysis, quality measures, quality improvement, patient safety
ORCID
0000-0002-9103-477X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Alan S Kliger's published research.
Publications Timeline
A big-picture view of Alan S Kliger's research output by year.
Karl Insogna, MD, FACP
John Wysolmerski, MD
Margaret Fikrig, MD
Fredric Finkelstein
Clare McGarvey Lambert, MD
Dana Dunne, MD, MHS, FACP, FIDSA
53Publications
2,483Citations
Publications
2024
Human Factors Contributing to Infection Prevention in Outpatient Hemodialysis Centers: A Mixed Methods Study
Parker S, Jesso M, Wolf L, Leigh K, Booth S, Gualandi N, Garrick R, Kliger A, Patel P. Human Factors Contributing to Infection Prevention in Outpatient Hemodialysis Centers: A Mixed Methods Study. American Journal Of Kidney Diseases 2024, 84: 18-27. PMID: 38447708, PMCID: PMC11193600, DOI: 10.1053/j.ajkd.2023.12.024.Peer-Reviewed Original ResearchCitationsAltmetricConceptsInfection preventionMultidisciplinary teamDialysis facilitiesMixed methods studyOutpatient hemodialysis centersOutpatient dialysis facilitiesOutpatient dialysis settingInfection prevention effortsOutpatient dialysis centersDialysis centersOutpatient careStaff conversationsMethods studyPrevention effortsStaff encounterDialysis settingAxial codingPrevention barriersAbstractText Label="RATIONALEMacroergonomic approachWork system designHemodialysis centersPreventionSample sizeQuantitative data
2023
Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency
Silberzweig J, Kliger A, White D, Stark S, Kumar V. Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency. Clinical Journal Of The American Society Of Nephrology 2023, 19: 263-265. PMID: 37642955, PMCID: PMC10861095, DOI: 10.2215/cjn.0000000000000303.Peer-Reviewed Original ResearchAltmetricSome Lessons Learned for Kidney Failure Patients in the COVID-19 Pandemic
Kliger A, Silberzweig J, McNamara E, Stark S. Some Lessons Learned for Kidney Failure Patients in the COVID-19 Pandemic. Clinical Journal Of The American Society Of Nephrology 2023, 18: 946-948. PMID: 36723343, PMCID: PMC10356111, DOI: 10.2215/cjn.0000000000000090.Peer-Reviewed Original ResearchCitationsAltmetricKidney Transplant Practice in Pandemic Times
Kumar V, Leigh K, Kliger A, Roberts G, Mohan S, Leca N, Sawinski D, Josephson M, Mannon R, Lentine K. Kidney Transplant Practice in Pandemic Times. Clinical Journal Of The American Society Of Nephrology 2023, 18: 961-964. PMID: 36795033, PMCID: PMC10356143, DOI: 10.2215/cjn.0000000000000092.Peer-Reviewed Original ResearchCitationsAltmetric54 COVID-19 and Dialysis Patients
Silberzweig J, Kliger A. 54 COVID-19 and Dialysis Patients. 2023, 491-496. DOI: 10.1016/b978-0-323-79135-9.00054-9.ChaptersConceptsDialysis therapyIntermittent renal replacement therapyCOVID-19Continuous dialysis therapyAcute kidney injuryChronic kidney diseaseRenal replacement therapyAcute peritoneal dialysisAssociated risk factorsHome dialysis therapiesHigh rateDepartment of HealthKidney injuryDiabetes mellitusDialysis patientsFacility patientsPeritoneal dialysisKidney diseaseReplacement therapyDialysis programRisk factorsSevere diseaseMedical conditionsSubstantial burdenPatients
2022
Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle KR, Wong L, St. Peter W, Roberts G, Rangaswami J, Mottl A, Kliger A, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC, Argyropoulos C, Quaggin SE. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1092-1103. PMID: 35649722, PMCID: PMC9269635, DOI: 10.2215/cjn.02980322.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and ConceptsConceptsDiabetic kidney diseaseKidney disease careKidney diseaseHealth care systemDisease careKidney failureGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsAngiotensin-converting enzyme inhibitorBreakthrough therapiesMajor public health challengeHealth care system supportCare systemAngiotensin receptor blockersCotransporter 2 inhibitorsHalf of patientsPocket drug costsIndividual health care systemsPublic health challengeHealth care professionalsValue-based careEligible patientsMineralocorticoid antagonistsCardiovascular events
2021
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius FC, Cherney D, Gee PO, Harris RC, Kliger A, Tuttle KR, Quaggin SE. Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2021, 16: 1590-1600. PMID: 34103350, PMCID: PMC8499007, DOI: 10.2215/cjn.18641120.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and ConceptsConceptsRenin-angiotensin system inhibitorsDiabetic kidney diseaseIrbesartan Diabetic Nephropathy TrialCare of patientsKidney diseaseSystem inhibitorsNew therapiesAngiotensin II Antagonist Losartan (RENAAL) trialAngiotensin II type 1 receptor blockerDiabetic kidney disease progressionType 1 receptor blockerCardiovascular protective therapiesReduction of EndpointsKidney disease progressionKidney protective effectsRenin-angiotensin systemDiabetic Nephropathy TrialRisk of deathHigh residual riskHealth care providersPowerful new therapiesNephropathy TrialReceptor blockersDevastating complicationAntihypertensive agentsSARS-CoV-2 Antibody Dynamics in Chronic Hemodialysis Patients
Thwin O, Grobe N, Ye X, Preciado P, Silva L, Cherif A, Wang Y, Kshirsagar A, Kliger A, Finkelstein F, Kotanko P. SARS-CoV-2 Antibody Dynamics in Chronic Hemodialysis Patients. Journal Of The American Society Of Nephrology 2021, 32: 770-770. DOI: 10.1681/asn.20213210s1770b.Peer-Reviewed Original Research
2012
The Authors Reply
Rocco M, Kliger A. The Authors Reply. Kidney International 2012, 82: 115. DOI: 10.1038/ki.2012.96.Commentaries, Editorials and Letters
2011
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.
Rocco MV, Lockridge RS, Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy CD, Lindsay RM, Levin NW, Ornt DB, Pierratos A, Pipkin MF, Rajagopalan S, Stokes JB, Unruh ML, Star RA, Kliger AS, Kliger A, Eggers P, Briggs J, Hostetter T, Narva A, Star R, Augustine B, Mohr P, Beck G, Fu Z, Gassman J, Greene T, Daugirdas J, Hunsicker L, Larive B, Li M, Mackrell J, Wiggins K, Sherer S, Weiss B, Rajagopalan S, Sanz J, Dellagrottaglie S, Kariisa M, Tran T, West J, Unruh M, Keene R, Schlarb J, Chan C, McGrath-Chong M, Frome R, Higgins H, Ke S, Mandaci O, Owens C, Snell C, Eknoyan G, Appel L, Cheung A, Derse A, Kramer C, Geller N, Grimm R, Henderson L, Prichard S, Roecker E, Rocco M, Miller B, Riley J, Schuessler R, Lockridge R, Pipkin M, Peterson C, Hoy C, Fensterer A, Steigerwald D, Stokes J, Somers D, Hilkin A, Lilli K, Wallace W, Franzwa B, Waterman E, Chan C, McGrath-Chong M, Copland M, Levin A, Sioson L, Cabezon E, Kwan S, Roger D, Lindsay R, Suri R, Champagne J, Bullas R, Garg A, Mazzorato A, Spanner E, Rocco M, Burkart J, Moossavi S, Mauck V, Kaufman T, Pierratos A, Chan W, Regozo K, Kwok S. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney International 2011, 80: 1080-91. PMID: 21775973, PMCID: PMC3569086, DOI: 10.1038/ki.2011.213.Peer-Reviewed Original Research
Academic Achievements and Community Involvement
activity Chair
Professional OrganizationsNIH / NIDDK Steering Committee for Consortium: Hemodialysis Novel Therapies (HDNT)Details2014 - Presenthonor Journal of the American Society of Nephrology Reviewer of the Year
National AwardAmerican Society of NephrologyDetails11/02/2023United Statesactivity Member
Professional OrganizationsNational Quality Forum Renal Standing CommitteeNational Quality Organization reviewing and recommending measures for quality careDetails06/01/2014 - 07/01/2023activity Member
Professional OrganizationsNational Quality Forum, Renal Standing CommitteeDetails07/01/2014 - 07/01/2023activity Chair
Professional OrganizationsNIH / NIDDK Steering Committee for Consortium: Hemodialysis Novel Therapies (HDNT)Details2014 - 2022
Links & Media
News
- January 10, 2022Source: Propublica
They Were The Pandemic’s Perfect Victims
- October 14, 2020
Thank You Voluntary Faculty
- September 30, 2020Source: HCP Live
Alan S. Kliger, MD: Negative COVID-19 Outcomes Common in Kidney Disease Patients
- August 23, 2020Source: The Philadelphia Inquirer
The coronavirus is damaging kidneys. Doctors worry that some survivors will need dialysis forever.
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
61 Rock Hill Road
Woodbridge, CT 06525
United States